Browse the evidence

GLP-1 receptor agonists (GLP-1RAs) are perceived by current and past users as safe and effective for weight loss, with users strongly disagreeing that risks outweigh benefits, whereas non-users exhibit significant skepticism regarding safety and efficacy.

If you are considering GLP-1RAs, be aware that skepticism about safety and cost are common barriers, especially if you haven't used them. However, data from current and past users shows they strongly disagree that risks outweigh benefits and highly recommend the medication. Consult a healthcare provider to address specific safety concerns and cost barriers, as user experience often contradicts public skepticism.

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) significantly reduce rheumatoid arthritis (RA) disease activity and pain in patients with RA and overweight or obesity, independent of the magnitude of weight loss.

If you have Rheumatoid Arthritis and are overweight, GLP-1 medications (like Ozempic or Mounjaro) may help reduce your joint pain and disease activity, not just help you lose weight. This benefit appears to come from the drug's direct effect on inflammation, not just the weight loss itself. Be aware that stomach side effects are common and insurance coverage can be a hurdle, but the potential for improved RA control is a significant clinical benefit to discuss with your rheumatologist.

Lorcaserin IR (twice daily) improves smoking cessation rates and prevents post-cessation weight gain in overweight or obese smokers compared to placebo.

If you smoke and are overweight, lorcaserin (10 mg twice daily) can help you quit smoking and prevent the weight gain that often follows. It works by reducing cravings and managing weight. This use is not FDA-approved, so discuss risks and benefits with your doctor.

GLP-1 receptor agonists (GLP-1RAs) provide modest antidepressant effects and reduce binge eating behaviors, but their impact on suicidality remains uncertain and potentially elevated in high-risk subgroups.

GLP-1 medications like semaglutide and liraglutide may help with mild depression and binge eating, especially if you have diabetes or obesity. However, if you have a history of severe mental health issues or take other psychiatric meds, monitor your mood closely as there may be a small increased risk of suicidal thoughts. The mental health benefits appear to come from direct brain effects, not just weight loss.

Combining Duodenal Mucosal Ablation (DMR) or Electroporation (ReCET) with GLP-1 receptor agonists (like Liraglutide or Semaglutide) can enable a majority of insulin-requiring T2D patients to eliminate exogenous insulin.

If you have Type 2 Diabetes and require insulin, ask your doctor about combining endoscopic procedures (like DMR or ReCET) with GLP-1 medications (like Semaglutide or Liraglutide). This combination has shown high success rates (up to 86% in small studies) in helping patients stop taking insulin. While it involves both a procedure and medication, the goal is to achieve insulin independence and better long-term control. This approach is still emerging, so discuss the risks and benefits with a specialist.

RYGB leads to a significant reduction in the use of antihypertensive and antidiabetic medications, even in patients who do not achieve total disease remission.

Even if surgery does not completely cure your diabetes or high blood pressure, it often allows you to significantly reduce or stop taking your medications. This reduces the burden of polypharmacy and potential side effects, improving overall metabolic health.

Preoperative optimization with GLP-1 agonists (specifically semaglutide 2.4 mg/week) enables patients with severe obesity (BMI ≥ 35 kg/m²) to achieve target BMI ≤ 35 kg/m², making them eligible for complex abdominal wall repair.

If you have severe obesity and need complex abdominal wall surgery, standard diet and exercise often fail to lower your BMI enough for safe surgery. Using GLP-1 agonists (like semaglutide) for about 8 months can help you lose enough weight (average 11.3%) to meet the safety threshold (BMI ≤ 35) for the procedure. This makes you eligible for surgery that might otherwise be denied or deemed too risky.

In adults with Type 1 Diabetes (T1D) and obesity (BMI ≥27 kg/m²), 12 months of treatment with GLP-1 receptor agonists (tirzepatide, semaglutide, or liraglutide) produces significant weight loss (7.1%–10.9%) without increasing the risk of severe hypoglycemia or diabetic ketoacidosis (DKA).

If you have Type 1 Diabetes and obesity, GLP-1 based medications (tirzepatide, semaglutide, or liraglutide) can help you lose significant weight (7-11%) over a year without increasing your risk of dangerous low blood sugar or DKA, provided your insulin regimen is stable. These drugs also modestly improve blood sugar control and reduce insulin needs.

Among GLP-1/GIP agonists used in Type 1 Diabetes, tirzepatide produces significantly greater weight loss (10.9%) compared to semaglutide (9.9%) and liraglutide (7.1%).

If you have Type 1 Diabetes and obesity, tirzepatide appears to offer the highest weight loss potential (approx. 11%) compared to semaglutide (approx. 10%) and liraglutide (approx. 7%) over 12 months, though all are effective.

GLP-1/GIP agonists reduce daily insulin requirements in Type 1 Diabetes patients by 8.3 to 11.4 units per day over 12 months, likely due to reduced insulin resistance.

Starting GLP-1/GIP agonists in T1D allows you to lower your daily insulin dose by approximately 8-11 units, which may help manage weight and insulin resistance without increasing hypoglycemia risk.

Self-reported increases in sweet and salty taste perception during GLP-1 or dual GIP/GLP-1 receptor agonist therapy are significantly associated with increased satiety, reduced appetite, and reduced food craving.

If you are taking a GLP-1 medication and notice your taste has changed (e.g., sweets taste stronger or saltier), this is a common and potentially helpful side effect. The research suggests these sensory changes are linked to feeling fuller faster and having fewer cravings, which supports your weight loss efforts. Do not be alarmed by these changes; they may be part of how the medication helps regulate your appetite.

Reducing the dosing frequency of GLP-1 receptor agonists (semaglutide and tirzepatide) after initial weight loss maintenance preserves a significant proportion of weight loss efficacy compared to once-weekly dosing, making it a viable strategy for long-term weight maintenance.

If you are maintaining weight loss on a GLP-1 agonist (like semaglutide or tirzepatide) and face supply issues or high costs, discuss extending the dosing interval with your provider. Instead of stopping completely, moving from weekly to every 10-14 days (or even 28 days for some) can maintain a significant portion of your weight loss (e.g., 50-70%) while saving money and extending supply. This is not a substitute for lifestyle changes but a viable maintenance strategy.

Initiating anti-obesity medications (AOMs) more than 12 months after bariatric surgery is associated with a significantly lower risk of adverse events compared to initiating them within the first 12 months.

If you are considering weight loss medication after bariatric surgery, current evidence suggests that waiting until at least 12 months post-surgery to start the medication is associated with a significantly lower risk of adverse events compared to starting within the first year. This may allow for better surgical recovery before adding pharmacological stress.

GLP-1 agonists (Liraglutide and Semaglutide) are promising interventions for reducing antipsychotic-induced weight gain, with Semaglutide showing superior efficacy to Liraglutide in general obesity populations, though evidence in SMI is still emerging.

GLP-1 medications like Liraglutide and Semaglutide show strong promise for counteracting weight gain from antipsychotics. Liraglutide has shown significant weight loss in SMI patients, and Semaglutide appears even more effective in general obesity studies. However, these require injections, which can be difficult for some patients, and more large-scale studies are needed to confirm long-term safety and efficacy in this specific group.

In elderly populations, NSAID use may not impair muscle growth and may even confer a positive hypertrophic effect by counteracting chronic inflammation that interferes with anabolic processes.

For elderly individuals, the use of NSAIDs might not hinder muscle growth and could potentially help by reducing chronic inflammation. Consult a doctor, as the risk-benefit profile differs from younger athletes.

GLP-1 receptor agonists (semaglutide, liraglutide) reduce binge eating episodes and food cravings in Binge Eating Disorder by modulating mesolimbic dopamine signaling and hypothalamic satiety pathways.

If you struggle with binge eating, current talk therapies may not be enough for long-term control. GLP-1 medications like semaglutide or liraglutide are showing promise in reducing the compulsive drive to binge by targeting brain reward circuits. While not yet a standard cure, they offer a biological lever to complement therapy. Discuss with a doctor if you have BED, as small trials show significant symptom reduction.

In patients with type 2 diabetes, subcutaneous semaglutide produces superior long-term weight loss compared to oral semaglutide over a two-year period.

If you have Type 2 Diabetes and are using semaglutide for weight loss, the injection form is significantly more effective than the pill form over the long term (2 years). You will likely lose more weight and have a higher chance of losing 10% or more of your body weight with the injection. However, if you are over 65, the oral pill might offer weight loss results similar to the injection, making it a viable alternative if you want to avoid needles.

GLP-1 receptor agonists (liraglutide, semaglutide) and GLP-1/GIP agonists (tirzepatide) produce significant weight loss in people with obesity without diabetes, but their use in postpartum women with previous gestational diabetes mellitus (GDM) is currently unsupported by evidence regarding safety, efficacy, and timing.

For women with a history of GDM, current guidelines recommend lifestyle modifications (diet and exercise) to reduce T2D risk, as pharmacological options like GLP-1 agonists lack safety and efficacy data for the postpartum period. While these drugs are effective for weight loss in the general obese population, they should not be used postpartum until further research clarifies their safety for mother and infant. Focus on sustainable lifestyle changes and regular monitoring.

Semaglutide 2.4 mg facilitates substantial, sustainable weight loss and improves cardiometabolic health by reducing 'food noise' and maladaptive eating behaviors.

Semaglutide 2.4 mg is an effective tool for reducing 'food noise' and enabling sustainable weight loss when lifestyle changes alone are insufficient. It works by altering hormonal signals related to appetite and satiety.

GLP-1RAs reduce emotional eating in the short term (3-6 months) by modulating reward processing, but this effect may not be long-lasting (12 months) and does not address underlying emotion regulation deficits.

GLP-1RAs like semaglutide can help reduce emotional eating for the first 3-6 months by changing how your brain responds to food rewards. However, this effect may fade after a year, and the medication does not fix the underlying emotional regulation skills. For lasting results, combine GLP-1RA treatment with emotion regulation therapies like CBT or DBT.

GLP-1 receptor agonists (e.g., semaglutide) and dual/triple agonists (e.g., tirzepatide) cause significant lean body mass loss (up to 40% of total weight loss), but this largely reflects reductions in non-contractile organs (liver, kidneys) rather than true skeletal muscle atrophy, with functional strength often preserved or improved.

If you are taking a GLP-1 drug like semaglutide, expect your total 'lean mass' number to drop significantly (up to 40% of weight lost). However, this is mostly water and organ mass (liver/kidneys), not your actual muscle fibers. Your strength likely stays the same or gets better because you are lighter. Focus on resistance training to maintain muscle quality, but do not panic about 'muscle wasting' as the primary driver of weight loss.

DJB implantation significantly improves glycemic control (HbA1c reduction) in patients with Type 2 Diabetes Mellitus.

For patients with Type 2 Diabetes, the DJB device can lower HbA1c levels from an average of 5.6% to 5.1% after one year. This improvement in blood sugar control is a key benefit alongside weight loss.

12 weeks of intense interval training significantly reduces the Visceral Adiposity Index (VAI) in women with Polycystic Ovary Syndrome (PCOS), but does not significantly alter serum adipose levels.

If you have PCOS, 12 weeks of high-intensity interval training (3x/week) can improve your visceral fat profile (VAI) without necessarily changing your serum adipose protein levels. Focus on the VAI improvement as a key health benefit, even if other blood markers remain stable.

Personalized nutrition improves postprandial glycemic response (PPGR) compared to control diets, with a median mean difference of -14.85 mg/dLxh.

Personalized nutrition significantly improves postprandial glycemic response (PPGR) compared to standard diets. This means blood sugar spikes after meals are better managed with personalized advice.